Cargando…

Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review

BACKGROUND: Gaucher disease (GD) is one of the most prevalent lysosomal storage diseases and is associated with hormonal and metabolic abnormalities, including nutritional status disorders, hypermetabolic state with high resting energy expenditures, peripheral insulin resistance, hypoadiponectinaemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kałużna, Małgorzata, Trzeciak, Isabella, Ziemnicka, Katarzyna, Machaczka, Maciej, Ruchała, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889605/
https://www.ncbi.nlm.nih.gov/pubmed/31791361
http://dx.doi.org/10.1186/s13023-019-1211-5
_version_ 1783475455174639616
author Kałużna, Małgorzata
Trzeciak, Isabella
Ziemnicka, Katarzyna
Machaczka, Maciej
Ruchała, Marek
author_facet Kałużna, Małgorzata
Trzeciak, Isabella
Ziemnicka, Katarzyna
Machaczka, Maciej
Ruchała, Marek
author_sort Kałużna, Małgorzata
collection PubMed
description BACKGROUND: Gaucher disease (GD) is one of the most prevalent lysosomal storage diseases and is associated with hormonal and metabolic abnormalities, including nutritional status disorders, hypermetabolic state with high resting energy expenditures, peripheral insulin resistance, hypoadiponectinaemia, leptin and ghrelin impairments, hypolipidaemia, linear growth deceleration and growth hormone deficiency, delayed puberty, hypocalcaemia and vitamin D deficiency. Specific treatments for GD such as enzyme replacement therapy and substrate reduction therapy display significant effects on the metabolic profile of GD patients. MAIN BODY OF THE ABSTRACT: Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1. GD1 appears to facilitate the development of disorders of nutrition, glucose metabolism and vitamin D insufficiency. Metabolic and hormonal diseases may have a significant impact on the course of the underlying disease and patient quality of life. CONCLUSIONS: Conditions relating to hormones and metabolism can be wide-ranging in GD1. Obtained findings were intrinsic to GD either as a deleterious process or a compensatory response and some changes detected may represent co-morbidities. Actively seeking and diagnosing endocrine and metabolic disorders are strongly recommended in GD1 patients to optimize healthcare.
format Online
Article
Text
id pubmed-6889605
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68896052019-12-11 Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review Kałużna, Małgorzata Trzeciak, Isabella Ziemnicka, Katarzyna Machaczka, Maciej Ruchała, Marek Orphanet J Rare Dis Review BACKGROUND: Gaucher disease (GD) is one of the most prevalent lysosomal storage diseases and is associated with hormonal and metabolic abnormalities, including nutritional status disorders, hypermetabolic state with high resting energy expenditures, peripheral insulin resistance, hypoadiponectinaemia, leptin and ghrelin impairments, hypolipidaemia, linear growth deceleration and growth hormone deficiency, delayed puberty, hypocalcaemia and vitamin D deficiency. Specific treatments for GD such as enzyme replacement therapy and substrate reduction therapy display significant effects on the metabolic profile of GD patients. MAIN BODY OF THE ABSTRACT: Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1. GD1 appears to facilitate the development of disorders of nutrition, glucose metabolism and vitamin D insufficiency. Metabolic and hormonal diseases may have a significant impact on the course of the underlying disease and patient quality of life. CONCLUSIONS: Conditions relating to hormones and metabolism can be wide-ranging in GD1. Obtained findings were intrinsic to GD either as a deleterious process or a compensatory response and some changes detected may represent co-morbidities. Actively seeking and diagnosing endocrine and metabolic disorders are strongly recommended in GD1 patients to optimize healthcare. BioMed Central 2019-12-02 /pmc/articles/PMC6889605/ /pubmed/31791361 http://dx.doi.org/10.1186/s13023-019-1211-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Kałużna, Małgorzata
Trzeciak, Isabella
Ziemnicka, Katarzyna
Machaczka, Maciej
Ruchała, Marek
Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review
title Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review
title_full Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review
title_fullStr Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review
title_full_unstemmed Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review
title_short Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review
title_sort endocrine and metabolic disorders in patients with gaucher disease type 1: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889605/
https://www.ncbi.nlm.nih.gov/pubmed/31791361
http://dx.doi.org/10.1186/s13023-019-1211-5
work_keys_str_mv AT kałuznamałgorzata endocrineandmetabolicdisordersinpatientswithgaucherdiseasetype1areview
AT trzeciakisabella endocrineandmetabolicdisordersinpatientswithgaucherdiseasetype1areview
AT ziemnickakatarzyna endocrineandmetabolicdisordersinpatientswithgaucherdiseasetype1areview
AT machaczkamaciej endocrineandmetabolicdisordersinpatientswithgaucherdiseasetype1areview
AT ruchałamarek endocrineandmetabolicdisordersinpatientswithgaucherdiseasetype1areview